Výsledky vyhledávání - "Toshimitsu Ochiai"

Akademický článek

Assessing the periprocedural magnitude of platelet count change in response to lusutrombopag

Autor: Robert S. Brown, Jr., Michio Imawari, Namiki Izumi, Yukio Osaki, Roy Bentley, Toshimitsu Ochiai, Takeshi Kano, Markus Peck-Radosavljevic

Publikováno v: JHEP Reports, Vol 3, Iss 2, Pp 100228- (2021)

Background & Aims: Despite limitations, platelet transfusion has been used to minimise bleeding risk in patients with thrombocytopaenia. Lusutrombopag is an oral, thrombopoietin receptor agonist approved for treatment of thrombocytopaenia associated

Externí odkaz: https://doaj.org/article/00c94837cc9149418baab00a32c04ccc

Zobrazit plný text záznamu

Pharmacokinetic Assessment and Treatment Effect of Lusutrombopag in Child–Pugh Class C Patients: Review of Patient Data from Two Clinical Studies and Post-Marketing Surveillance

Autor: Steven L, Flamm, Markus, Peck-Radosavljevic, Takahiro, Fukuhara, Roy, Bentley, Takayuki, Katsube, Toshimitsu, Ochiai, Takeshi, Kano, Eri, Tsukimura, Ritsue, Sasaki, Yukio, Osaki

Publikováno v: Advances in Therapy. 39:4285-4298

Patients with thrombocytopenia and chronic liver disease are at increased risk of bleeding during invasive procedures due to low platelet counts. Lusutrombopag, an orally active thrombopoietin receptor agonist, increases platelet count and reduces th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::206f7866cf246432e29f5fded54da2a4
https://doi.org/10.1007/s12325-022-02237-8

Zobrazit plný text záznamu

Efficacy of duloxetine in patients with knee osteoarthritis or chronic low back pain with early pain reduction: An exploratory post-hoc analysis of Japanese phase 3, 1-year extension studies

Autor: Yuji Uchio, Shinichi Konno, Toshinaga Tsuji, Toshimitsu Ochiai, Naohiro Itoh, Mitsuhiro Ishida

Publikováno v: Journal of Orthopaedic Science. 27:717-724

Two previous phase 3, double-blind, randomized, placebo-controlled trials showed that duloxetine 60 mg/day for 14 weeks significantly improved pain and quality of life in Japanese patients with knee osteoarthritis or chronic low back pain. In their o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::360fbc8927c59e5bd2e187586109e945
https://doi.org/10.1016/j.jos.2021.02.016

Zobrazit plný text záznamu

The Relationship Between Baseline Clinical Symptom Characteristics and Working Ability in Japanese Patients Treated for Major Depressive Disorder and Painful Physical Symptoms

Autor: Toshinaga Tsuji, Shinji Hayashi, Kazutaka Shimoda, Norio Sugawara, Yoshikazu Ajisawa, Hideyuki Imagawa, Norio Yasui-Furukori, Toshimitsu Ochiai

Publikováno v: Neuropsychiatric Disease and Treatment

Norio Sugawara,1,* Norio Yasui-Furukori,1,* Toshinaga Tsuji,2 Shinji Hayashi,2 Yoshikazu Ajisawa,3 Toshimitsu Ochiai,3 Hideyuki Imagawa,4 Kazutaka Shimoda1 1Department of Psychiatry, Dokkyo Medical University School of Medicine, Tochigi, Japan; 2Medi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a76a1b7954b805c207f2d3ff18dc0162
https://doi.org/10.2147/ndt.s274608

Zobrazit plný text záznamu

Is platelet monitoring during 7‐day lusutrombopag treatment necessary in chronic liver disease patients with thrombocytopenia undergoing planned invasive procedures? A phase IIIb open‐label study

Autor: Takahiro Fukuhara, Takayuki Katsube, Kazushi Numata, Michio Imawari, Katsuaki Tanaka, Namiki Izumi, Toshimitsu Ochiai, Yukio Osaki, Takeshi Kano

Publikováno v: Hepatology Research. 50:1141-1150

Aim Lusutrombopag is approved for thrombocytopenia in chronic liver disease patients planned to undergo invasive procedures. In previous clinical studies, lusutrombopag treatment was stopped in patients with an increase in platelet count (PC) of ≥2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33a23660f86a544b3041d2d380ec4997
https://doi.org/10.1111/hepr.13544

Zobrazit plný text záznamu

Plný text ve formátu HTML

Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L‐PLUS 2)

Autor: Toshimitsu Ochiai, Markus Peck-Radosavljevic, Tomoko Motomiya, Mihaly Makara, Marius Braun, Sheng-Shun Yang, Nezam H. Afdhal, Zeid Kayali, Ziv Ben Ari, Ajay Duggal, Tsutae Nagata, Paul Mitrut, Meral Akdogan, A. Iacobellis, Albert Tran, Krzysztof Simon, Takeshi Kano, Tarek Hassanein, Mario Pirisi

Publikováno v: Hepatology (Baltimore, Md.)

Thrombocytopenia may be associated with increased bleeding risk impacting timing and outcome of invasive procedures in patients with chronic liver disease (CLD). Lusutrombopag, a small-molecule, thrombopoietin (TPO) receptor agonist, was evaluated as

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::664a75576e89efc2731a97412d3e542d
https://doi.org/10.1002/hep.30561

Zobrazit plný text záznamu

Assessing the periprocedural magnitude of platelet count change in response to lusutrombopag

Autor: Yukio Osaki, Robert S. Brown, Toshimitsu Ochiai, Namiki Izumi, Markus Peck-Radosavljevic, Michio Imawari, Takeshi Kano, Roy Bentley

Publikováno v: JHEP Reports
JHEP Reports, Vol 3, Iss 2, Pp 100228-(2021)

Background & Aims Despite limitations, platelet transfusion has been used to minimise bleeding risk in patients with thrombocytopaenia. Lusutrombopag is an oral, thrombopoietin receptor agonist approved for treatment of thrombocytopaenia associated w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0179199a2371e936972820821eea2ee5
http://europepmc.org/articles/PMC7887643

Zobrazit plný text záznamu

Lusutrombopag Is Safe and Efficacious for Treatment of Thrombocytopenia in Patients With and Without Hepatocellular Carcinoma

Autor: Namiki Izumi, Naim Alkhouri, Yukio Osaki, Takeshi Kano, Michio Imawari, Toshimitsu Ochiai, Roy Bentley, Franco Trevisani

Background & Aims: Patients with hepatocellular carcinoma (HCC) secondary to chronic liver disease often require invasive procedures but frequently have thrombocytopenia. Lusutrombopag is an agonist of the thrombopoietin receptor that activates plate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79a63125ebca640a51d06999dfd04d9a
https://hdl.handle.net/11585/803434

Zobrazit plný text záznamu

A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation

Autor: Yukio Osaki, Seiji Kawazoe, Kazuhide Yamamoto, Mineo Kurokawa, Katsuaki Tanaka, Takahiro Fukuhara, Takayuki Katsube, Toshimitsu Ochiai, Masatoshi Kudo, Takeshi Kano, Michio Imawari, Hideyuki Tamai, Ryosuke Tateishi, Masataka Seike, Namiki Izumi

Publikováno v: Journal of Gastroenterology

Background Thrombocytopenia represents an obstacle for invasive procedures in chronic liver disease (CLD) patients. We aimed to estimate the appropriate dose and evaluate the efficacy and safety of lusutrombopag for the treatment of thrombocytopenia

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7126f1e021cedb7fb53559467a0bab9
https://doi.org/10.1007/s00535-018-1499-2

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání